X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Adam Craig Sells 47,436 Shares

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Chairman Adam Craig sold 47,436 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the transaction, the chairman owned 328,651 shares of the company’s stock, valued at $1,459,210.44. This represents a 12.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ XFOR opened at $4.29 on Friday. X4 Pharmaceuticals, Inc. has a 52-week low of $2.45 and a 52-week high of $4.83. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.98 and a current ratio of 10.18. The business has a fifty day moving average of $4.04 and a two-hundred day moving average of $3.96. The stock has a market cap of $425.35 million, a PE ratio of -3.57 and a beta of 0.37.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its earnings results on Friday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. The business had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 64.95%. As a group, equities research analysts expect that X4 Pharmaceuticals, Inc. will post -0.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on XFOR. Wells Fargo & Company assumed coverage on X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 target price on the stock. Weiss Ratings downgraded X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Finally, Leerink Partners started coverage on X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, X4 Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $11.25.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of institutional investors have recently modified their holdings of XFOR. Rhumbline Advisers grew its stake in shares of X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares during the last quarter. Pettinga Financial Advisors LLC acquired a new position in X4 Pharmaceuticals during the 2nd quarter worth $47,000. Indivisible Partners acquired a new position in X4 Pharmaceuticals during the 4th quarter worth $40,000. SummitTX Capital L.P. bought a new position in X4 Pharmaceuticals in the 1st quarter valued at $46,000. Finally, Squarepoint Ops LLC bought a new position in X4 Pharmaceuticals in the 4th quarter valued at $50,000. 72.03% of the stock is owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.